

## **2024 ASTCT Fundamentals of HCT Virtual Training Course**

**April 19, 2024 - April 20, 2024**

### **TARGET AUDIENCE**

The target audience for this activity includes pharmacists and physicians, including new practitioners, residents, fellows, and all other healthcare providers training in this discipline.

### **PROGRAM OVERVIEW**

The Fundamentals of HCT Training Course is a 2-day conference that provides a broad overview and introduction of hematopoietic cell transplantation (HCT), also referred to as blood and marrow transplantation (BMT), as well as cellular immunotherapy (CI). Throughout the lectures, participants will be introduced to numerous aspects of the HCT-CI processes, which are designed to develop or enhance skills required in the management of patients undergoing these procedures. This course incorporates case-based learning to emphasize application of concepts taught through didactic lecture with a strong focus on the pharmacotherapeutic management.

The Fundamentals of HCT Training Course is designed to inform attendees about the latest developments in 1) treatment guidelines; 2) therapeutic regimens; 3) diseases state management; 4) supportive care therapies; 5) controversial care issues; and 6) clinical trial data.

### **LEARNING OBJECTIVES**

- Discuss current clinical practice and challenges for healthcare professionals in the field of hematopoietic cell transplantation (HCT) and cellular immunotherapy
- Identify best practice strategies and clinical challenges related to pre-transplant evaluation, donor selection, stem cell mobilization, conditioning, immune effector cell therapy, peri-transplant complications, pulmonary complications, viral infections, fungal infections, acute graft versus host disease, chronic graft versus host disease, thrombotic microangiopathy, cytopenia post-transplant, geriatrics, and pediatrics
- Examine patient case studies related to stem cell mobilization, conditioning, immune effector cell therapy, viral infections, fungal infections, acute graft versus host disease, chronic graft versus host disease, veno-occlusive disease/sinusoidal obstruction syndrome, thrombotic microangiopathy, geriatrics and pediatrics

### **INSTRUCTIONS FOR PARTICIPATION AND REQUESTING CREDIT**

There are no fees for participating and receiving credit for this activity. Successful completion is achieved by reviewing the CE information, completing the activity, and completing the evaluation form.

### **Credit Fulfillment**

- If you are requesting AMA credits or a certificate of participation, your certificate will be available for download.
- If you are a pharmacist requesting ACPE credits, your credit request will be uploaded to CPE Monitor within 60 days after the activity.

Note: There is ONE evaluation for the entire program, not one for each individual session. A link for the CE evaluation will be provided post-conference.

Technical Requirements: <http://www.francefoundation.com/general-requirements.html>

## **ACCREDITED PROVIDER**

This activity is jointly provided by The France Foundation and the American Society for Transplantation and Cellular Therapy (ASTCT).



## **Accreditation Statement**



In support of improving patient care, this activity has been planned and implemented by The France Foundation and the American Society for Transplantation and Cellular Therapy (ASTCT). The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

JOINTLY ACCREDITED PROVIDER™  
INTERPROFESSIONAL CONTINUING EDUCATION

## **PHYSICIAN CREDIT DESIGNATION**



The France Foundation designates this live activity for a maximum of 15.25 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## **NURSES**



The France Foundation designates this activity for 15.25 contact hours.

## **PHARMACISTS**



This knowledge and application-based activity qualifies for 15.25 contact hours (0.1525 CEUs) of continuing pharmacy education credit. **Please submit all evaluations and credit requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date.** Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service ([custserv@nabp.net](mailto:custserv@nabp.net)).

All other healthcare professionals completing this course will be issued a statement of participation.

## Program Agenda

Friday, 4/19/2024 (CDT)	Topic		Hours (CEUs)	UAN #s	
8:00 – 8:10 AM	<b>Welcome &amp; Opening Remarks</b> Susie Long, PharmD; University of Minnesota, Minneapolis, MN				
8:10 – 8:40 AM	<b>Introduction to HCT</b> Jason Ernstberger, PharmD, BCOP; University of Cincinnati Medical Center, Cincinnati, OH		0.5 (0.05)	JA0007204-9999-24-021-L01-P	
8:45 – 9:30 AM	<b>Pre-Transplant Evaluation</b> Andrea Fadel, BSN, RN, OCN, BMTCN; University of Chicago Medicine, Chicago, IL		0.75 (0.075)	JA0007204-9999-24-022-L01-P	
9:35 – 10:35 AM	<b>Donor Selection Debate</b> Shatha Farhan, MD; Henry Ford Health, Detroit, MI Ioannis Politikos, MD; Memorial Sloan Kettering Cancer Center, New York City, NY Marco Ruiz, MD; Baptist Health Miami Cancer Institute, Miami, FL		1.0 (0.1)	JA0007204-9999-24-023-L01-P	
10:35 – 10:45 AM (10)	<b>BREAK</b>				
10:45 – 11:30 AM	<b>Hematopoietic Stem Cell Mobilization</b> Erika Wass, PharmD, BCOP; Loma Linda University Medical Center, Loma Linda, CA		0.75 (0.075)	JA0007204-9999-24-024-L01-P	
11:35 – 12:35 PM	<b>Principles of Conditioning in Hematopoietic Stem Cell Transplant</b> Taiga Nishihori, MD; Moffitt Cancer Center, Tampa, FL		1.0 (0.1)	JA0007204-9999-24-025-L01-P	
12:35 – 1:05 PM (30)	<b>LUNCH</b>				
1:05 – 2:05 PM	<b>Special Populations in HCT: Pediatrics</b> Susie Long, PharmD; University of Minnesota, Minneapolis, MN	<b>Special Populations in HCT: Geriatrics</b> Andrew Artz, MD; City of Hope, Los Angeles, CA	1.0 (0.1)	JA0007204-9999-24-026-L01-P	JA0007204-9999-24-027-L01-P
2:10 – 3:25 PM	<b>Supportive Care for Peri-Transplant Complications</b> Amber Clemmons, PharmD, BCOP; University of Georgia, Augusta, GA		1.25 (0.125)	JA0007204-9999-24-028-L01-P	
3:25 – 3:35 PM (10)	<b>BREAK</b>				
3:35 – 4:20 PM	<b>Transplant Associated Thrombotic Microangiopathy</b> Hemalatha Rangarajan, MD; Nationwide Children's Hospital, Columbus, OH	<b>Pulmonary Complications of HCT</b> Suzanne Gettys, PharmD, BCOP; MD Anderson Cancer Center, Houston, TX	0.75 (0.075)	JA0007204-9999-24-029-L01-P	JA0007204-9999-24-030-L01-P
4:25 – 4:55 PM	<b>Patient Case: Veno Occlusive Disease / Sinusoidal Obstructive Syndrome</b> Katie Gatwood, PharmD, BCOP; Vanderbilt University, Nashville, TN		0.5 (0.05)	JA0007204-9999-24-031-L01-P	
5:00 – 5:30 PM	<b>Virtual Roundtable Discussion &amp; Wrap-Up (*No CE provided)</b>				
	<b>Day 1 Concludes</b>		<b>7.5 (0.75)</b>		

Saturday, 4/20/2024 (CDT)	Topic		Hours (CEUs)	UAN #s	
8:00 – 9:00 AM	<b>Viral Infections in Hematopoietic Stem Cell Transplant</b> LeAnne Kennedy, PharmD, BCOP; Wake Forest University, Winston-Salem, NC		1.0 (0.1)	JA0007204-9999-24-032-L01-P	
9:05 – 9:50 AM	<b>Fungal Infections in Hematopoietic Stem Cell Transplant</b> Arpita Gandhi, PharmD, BCOP; Emory Healthcare - Winship Cancer Institute, Atlanta, GA		0.75 (0.075)	JA0007204-9999-24-033-L01-P	
9:55 – 10:55 AM	<b>Patient Case: Navigating Cytopenia Post Transplant</b> Forat Lufti, MD; University of Kansas Medical Center, Kansas City, KS		1.0 (0.1)	JA0007204-9999-24-034-L01-P	
10:55 – 11:05 AM (10)	<b>BREAK</b>				
11:05 – 12:20 PM	<b>Acute Graft versus Host Disease</b> Elizabeth DiMaggio, PharmD, BCOP; Moffitt Cancer Center, Tampa, FL		1.25 (0.125)	JA0007204-9999-24-035-L01-P	
12:20 – 12:50 PM (30)	<b>LUNCH</b>				
12:50 – 2:05 PM	<b>Chronic Graft versus Host Disease</b> Rebecca Gonzalez, PharmD, BCOP; Moffitt Cancer Center, Tampa, FL		1.25 (0.125)	JA0007204-9999-24-036-L01-P	
2:05 – 2:15 PM (10)	<b>BREAK</b>				
2:15 – 3:00 PM	<b>Patient Case: Engraftment Syndrome</b> Brooke Adams, PharmD, BCOP; University of Florida Health Shands, Gainesville, FL	<b>Patient Case: Steroid Refractory GVHD</b> Molly Gallogly, MD, PhD; University Hospitals Cleveland Medical Center	0.75 (0.075)	JA0007204-9999-24-037-L01-P	JA0007204-9999-24-038-L01-P
3:05 – 3:50 PM	<b>Immune Effector Cell Products and Indications</b> Jennifer Collins, PharmD, BCOP; University of Chicago Medicine, Chicago, IL		0.75 (0.075)	JA0007204-9999-24-039-L01-P	
3:55 – 4:55 PM	<b>Management of Immune Effector Cell Toxicity and Complications</b> Cameron Ninos, PharmD, BCOP; University of Wisconsin – Madison, Madison, WI		1.0 (0.1)	JA0007204-9999-24-040-L01-P	
4:55 – 5:05 PM (10)	<b>BREAK</b>				
5:05 – 5:30 PM	<b>Virtual Roundtable Discussion &amp; Wrap-Up (*No CE provided)</b>				
	<b>Day 2 Concludes</b>		<b>7.75 (0.775)</b>		

## **DISCLOSURE POLICY**

The France Foundation (TFF) and The American Society for Transplantation and Cellular Therapy (ASTCT) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and ASTCT resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and ASTCT seek to verify that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ASTCT are committed to providing learners with high-quality CE activities that promote improvements in health care and not those of a commercial interest.

Disclosures for members of the planning committee and faculty will be disclosed to learners prior to the conference and can also be found [here](#).

### **Disclosure of Unlabeled Use:**

The France Foundation (TFF) and The American Society for Transplantation and Cellular Therapy (ASTCT) require CE faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational. They must also disclose limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off label use of these medications. TFF and ASTCT do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

### **Disclaimer:**

The France Foundation and the American Society for Transplantation and Cellular Therapy present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, The American Society for Transplantation and Cellular Therapy, and the commercial supporter(s) assume no liability for the information herein.

## **CONTACT INFORMATION**

**If you have questions about this CME/CE activity, please contact The France Foundation at 860-434-1650 or [info@francefoundation.com](mailto:info@francefoundation.com).**